Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal Immunization With MenAfriVac
NCT03746665Phase 3Unknown
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label trial of MenAfriVac in meningococcal meningitis and Tetanus (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Meningococcal serogroup A serum bactericidal activity Geometric Mean Titre at 9 months, Percentage tetanus toxoid seroprotection and 5 more. Status: unknown.
02
Drugs
MenAfriVac
03
Conditions
meningococcal meningitisTetanus
Beyond the preview
Go deeper on NCT03746665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746665.